According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

The mean baseline blood glucose levels (expressed in mg/dL) were 88.2±9.0 for oral DehydraTECH-tirzepatide and 87.8±11.3 for injected Zepbound®, compared to the Study-ending levels of 83.2±5.7 and ...

In their respective third-quarter earnings reports, the companies tallied sales of $1.26 billion for Zepbound—falling short ...